The Expanding Treatment Armamentarium and Clinical Decision Making: ExteNET, DestinyBREAST-05, HER2CLIMB, and Other Emerging Trials
Dr. Tarantino discuss the integration of recent trial data into post-neoadjuvant treatment strategies, comparing adjuvant T-DM1 with pertuzumab plus trastuzumab.
Video content above is prompted by the following:
- How might these data factor into your treatment considerations post neoadjuvant treatment?
- When would you recommend adjuvant T-DM1 over adjuvant pertuzumab plus trastuzumab in this setting?
- With a growing number HER2-targeting agents available, how do you approach the decision-making process in your practice? Please comment on other trials investigating HER2 targeting agents?
- Trastuzumab
- Tucatinib
- Neratinib
- How do you evaluate and compare data from clinical trials for these agents?
- What are the factors you consider when selecting between HER2-targeted agents?
- What are your considerations for optimal sequencing of these therapies?
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
